News
-
-
-
COMMUNIQUÉ DE PRESSE
Redcare Pharmacy confirms full-year guidance following sustained positive Q3 sales performance in both Rx and non-Rx.
Redcare Pharmacy N.V. confirms full-year guidance with positive Q3 sales growth. Total sales up 25% to EUR 719M, active customers reach 13.7M, Rx sales in Germany surged 82% -
COMMUNIQUÉ DE PRESSE
Euronext announces the launch of the voluntary exchange offer for all ATHEX shares
Euronext launches voluntary exchange offer to acquire all ATHEX shares, boosting integration and competitiveness in the European capital market. Strategic rationale, details of offer, and timetable provided -
COMMUNIQUÉ DE PRESSE
Sentorise Launches 12.8V 100Ah Group 31 LiFePO₄ Battery, Delivering Safe, Smart, and Sustainable Power
Sentorise launches the 12.8V 100Ah Group 31 LiFePO4 battery in Europe, offering advanced safety features, Bluetooth connectivity, and long lifespan for RVs, off-grid homes, and marine use -
COMMUNIQUÉ DE PRESSE
Sentorise lance sa batterie LiFePO₄ 12,8V 100Ah format Group 31 : une énergie sûre, intelligente et durable
Sentorise annonce le lancement européen de sa batterie LiFePO4 12,8V 100Ah au format Group 31, offrant sécurité, longue durée de vie et surveillance Bluetooth. Certification UN38.3 et conformité CE, RoHS, REACH. Certification RCS/GRS en cours -
COMMUNIQUÉ DE PRESSE
Bus World 2025: CRRC EV Debuts Two All-Electric Buses, Introduces Digital-Intelligent Low-Carbon Urban Transit System to Redefine Smarter Urban Mobility
CRRC EV unveils two groundbreaking all-electric buses at Busworld Europe 2025 Congress, introducing their Digital-Intelligent Low-Carbon Urban Transit System -
-
COMMUNIQUÉ DE PRESSE
Abivax Announces Late-Breaking Presentation of 8-Week ABTECT Trial Results with Updated Safety Data
Abivax announces positive results from Phase 3 ABTECT 8-Week Induction Trials on obefazimod for ulcerative colitis treatment with no new safety concerns identified, to present further abstract on October 6 -
COMMUNIQUÉ DE PRESSE
Abivax annonce la présentation des derniers résultats de l'essai ABTECT de 8 semaines avec des données de tolérance actualisées
Abivax annonce la présentation des derniers résultats de l'essai ABTECT de 8 semaines avec des données de tolérance actualisées lors de la Semaine UEG à Berlin. Obefazimod atteint les critères clés d'évaluation dans le traitement de la rectocolite hémorragique
